华东医药：迈华替尼片是公司早期研发的创新药

Core Viewpoint - Huadong Medicine (000963) is optimistic about its future development and is committed to efficiently advancing research and commercialization to provide stable returns to investors [1] Group 1: Company Development - Huadong Medicine's Maihua Tini tablets are an innovative drug developed by the company [1] - The company's research and development system has matured over recent years, leading to improved efficiency in regulatory communication [1] - The clinical development cycle for subsequent innovative drug projects has been significantly optimized, aligning with industry norms [1] Group 2: Strategic Planning - The company has established a clear strategic plan based on research progress and market trends [1] - Future operational plans will be detailed in the company's upcoming periodic reports and related announcements [1]